Clinical detection of human probiotics and human pathogenic bacteria by using a novel high-throughput platform based on next generation sequencing

Table 4 The result of disease risk evaluations of 12 samples

Disease	B011	B012	B013	B014	B016	B017	B018	B019	B020	B031	B033	B034
*Constipation*	2.67E-01	2.67E-01	2.67E-01	1.00E + 00	1.00E + 00	2.67E-01	1.00E + 00	1.00E + 00	2.67E-01	3.34E-02	2.67E-01	1.00E + 00
*Obesity*	1.34E-01	1.34E-01	1.00E + 00	1.34E-01	1.00E + 00	1.34E-01	1.34E-01	1.00E + 00	1.00E + 00	1.34E-01	1.00E + 00	2.57E-03
*IBS*	3.33E-01	7.06E-01	1.00E + 00	3.33E-01	1.00E + 00	3.33E-01	3.33E-01	1.00E + 00	1.10E-01	1.10E-01	7.06E-01	3.33E-01
*Ulcerative colitis*	9.30E-02	4.15E-01	1.00E + 00	4.15E-01	1.00E + 00	9.30E-02	4.15E-01	1.00E + 00	9.30E-02	1.00E + 00	1.00E + 00	1.00E + 00
*Colorectal cancer*	4.88E-01	2.59E-01	9.35E-01	7.47E-01	7.47E-01	7.47E-01	2.59E-01	4.88E-01	4.88E-01	1.22E-02	7.47E-01	1.22E-02
*Atopic dermatitis*	1.83E-01	1.00E + 00	1.00E + 00	1.00E + 00	1.00E + 00	1.83E-01	1.83E-01	1.00E + 00	1.00E + 00	1.00E + 00	1.00E + 00	1.83E-01
*Allergic rhinitis*	1.89E-01	1.00E + 00	1.00E + 00	1.00E + 00	1.00E + 00	1.89E-01	1.89E-01	1.89E-01	1.00E + 00	1.89E-01	1.00E + 00	1.89E-01

The bold numbers represent two samples had reached significance level with P-value less than 0.05 of distribution in three diseases compared to 98 sample control group using evaluation model.